UROGEN PHARMA LTD
- Country
- 🇮🇱Israel
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 201
- Market Cap
- -
- Website
- http://www.urogen.com
The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study
- Conditions
- Interventions
- First Posted Date
- 2016-06-08
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- UroGen Pharma Ltd.
- Target Recruit Count
- 71
- Registration Number
- NCT02793128
- Locations
- 🇺🇸
University of California, Los Angeles, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸John Hopkins University, Baltimore, Maryland, United States
Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2")
- Conditions
- Interventions
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- UroGen Pharma Ltd.
- Registration Number
- NCT02674269
- Locations
- 🇮🇱
Meir Medical Center, Kfar Saba, Israel
🇮🇱Rambam Health Care Campus, Haifa, Israel
Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- UroGen Pharma Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT02307487
- Locations
- 🇮🇱
Wolfson Medical Center of Holon, Department of Urology, Holon, Israel
🇮🇱Meir Medical Center, Kfar Saba, Israel
Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients
- First Posted Date
- 2014-07-01
- Last Posted Date
- 2016-03-01
- Lead Sponsor
- UroGen Pharma Ltd.
- Target Recruit Count
- 3
- Registration Number
- NCT02179099
- Locations
- 🇮🇱
Urology Department, Edith Wolfson Medical Center, Holon, Israel
Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients
- Conditions
- Interventions
- First Posted Date
- 2013-11-28
- Last Posted Date
- 2016-04-12
- Lead Sponsor
- UroGen Pharma Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT01997983
- Locations
- 🇮🇱
Assaf Harofeh Medical Center, Zerifin, Israel
Pre-TURBT TC-3 Gel Intravesical Instillation in NMIBC
- Conditions
- Interventions
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- UroGen Pharma Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT01803295
- Locations
- 🇪🇸
Fundacio Puigvert, Barcelona, Spain
🇮🇱Carmel Medical Center of Haifa, Department of Urology, Haifa, Israel
🇮🇱Rambam Health Care Campus, Haifa, Israel
A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)
- Conditions
- Interventions
- First Posted Date
- 2013-02-26
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- UroGen Pharma Ltd.
- Registration Number
- NCT01799499
- Locations
- 🇮🇱
Western Galilee Hospital Nahariya, Nahariya, Israel
Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel Device In Patients With Muscle Invasive Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-07-24
- Last Posted Date
- 2013-05-07
- Lead Sponsor
- UroGen Pharma Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT01648010
- Locations
- 🇮🇱
Wolfson, Holon, Israel
🇮🇱Barzilai Hospital, Ashkelon, Israel
🇮🇱Beilinson, Petah-Tikva, Israel